Percheron Therapeutics is a clinical stage biotech company focused on rare diseases. The company's lead asset is ATL1102, an antisense oligonucleotide which targets CD49d, an adhesion ligand on T-lymphocytes. ATL1102 was developed through a collaboration with Ionis Pharmaceuticals (NASDAQ: IONS). The drug is current the subject of an international phase IIb study in Duchenne muscular dystrophy, with data expected in 4Q CY2024. ATL1102 has been granted orphan drug designation and rare pediatric disease designation by FDA.